Calliditas Therapeutics Presents New NefIgArd Trial Data Supporting Nefecon's Gut-Targeted Mechanism in IgA Nephropathy
核心洞察
Calliditas Therapeutics will present seven abstracts at the 2026 World Congress of Nephrology, including new secondary analyses from the Phase 3 NefIgArd study evaluating Nefecon (搜索)'s effects on gut-associated lymphoid tissue (搜索) biomarkers in IgA nephropathy (搜索) patients.
The presentations will highlight mechanistic data demonstrating Nefecon (搜索)'s immunomodulatory effects in Peyer's patches (搜索), reinforcing its disease-modifying role in reducing pathogenic galactose-deficient IgA1 (搜索) levels.
Additional data will include proteinuria response analyses and preliminary efficacy findings from a Phase 2a trial of setanaxib in Alport syndrome (搜索) patients.
Calliditas Therapeutics AB, an Asahi Kasei (搜索) company, announced new data from its Phase 3 NefIgArd study in primary immunoglobulin A nephropathy (IgAN) will be presented at the 2026 World Congress of Nephrology in Yokohama, Japan, from March 28-31. The presentations will provide additional evidence supporting Nefecon (搜索)'s gut-targeted, disease-modifying mechanism of action in treating this rare kidney disease.
New Mechanistic Insights into Nefecon's Action
The company will present secondary analyses from the Phase 3 NefIgArd study evaluating Nefecon (搜索)'s effects on serum biomarkers associated with gut-associated lymphoid tissue (搜索) (GALT) activity. These findings demonstrate the immunomodulatory effects in the Peyer's patches (搜索) that underlie Nefecon's mechanism of action in modulating the mucosal immune system in the gut.
One key presentation will examine the immunological impact of orally administered budesonide on B- and T-cell subsets in murine Peyer's patches (搜索) following in vivo stimulation. These findings reinforce observations from earlier exploratory biomarker analyses and collectively support a disease-modifying role for Nefecon (搜索) in reducing levels of pathogenic galactose-deficient IgA1 (搜索) in patients with IgAN.
Comprehensive Data Package
Calliditas will present seven abstracts in total, with three based on secondary clinical efficacy and safety analyses from the Phase 3 NefIgArd study and two on mechanistic/biomarker analyses. The presentations will include analyses of urine protein-creatinine ratio response at 12 months, duration of absolute proteinuria response over the 2-year NefIgArd trial, and absolute proteinuria changes over time with Nefecon (搜索) versus placebo.
The company will also present initial demographics from the PERFORM Patient Registry, a novel real-world registry of patients treated for IgA nephropathy (搜索) in the United States. Additionally, safety and preliminary efficacy findings from a Phase 2a randomized, double-blind, placebo-controlled trial of setanaxib in patients with Alport syndrome (搜索) will be shared.
Educational Symposium on Treatment Evolution
Calliditas will sponsor a scientific symposium titled "The Evolving IgAN Treatment Paradigm: Why Target the Gut?" featuring presentations from Dr. Yusuke Suzuki of Juntendo University in Tokyo, Dr. Sayna Norouzi of Loma Linda University Medical Center, and Dr. Chee Kay Cheung of the University of Leicester.
About Nefecon/TARPEYO
TARPEYO is an oral 4mg delayed-release formulation of budesonide, designed to dissolve in the pH of the distal ileum. Each capsule contains coated beads of budesonide that target mucosal B-cells present in the ileum, including the Peyer's patches (搜索), which are responsible for the production of galactose-deficient IgA1 (搜索) antibodies causing IgA nephropathy (搜索).
The drug is approved in the United States as TARPEYO for reducing the loss of kidney function in adults with primary IgAN who are at risk for disease progression. It is available in Europe as Kinpeygo marketed by STADA Arzneimittel AG and in select Asian countries including Mainland China, Hong Kong, Macau, Taiwan, Singapore, and South Korea by Everest Medicines (搜索).
Understanding IgA Nephropathy
Primary immunoglobulin A nephropathy is a rare, progressive, chronic immune-mediated disease that attacks the kidneys. It occurs when galactose-deficient IgA1 (搜索) is recognized by autoantibodies, creating IgA1 containing immune complexes that become deposited in the glomerular mesangium of the kidney. This deposition can lead to progressive kidney damage, potentially resulting in end-stage kidney disease (搜索). IgAN most often develops between late teens and late 30s.